SVRA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SV

Mkt Cap

$915.1M

Volume

2.02M

Next Earnings

November 11th

Loading chart

SV

SVRASavara Inc.

SVRA

Pay with—

Available Balance0.00

SV

Mkt Cap

$973.9M

Volume

2.02M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Savara Announces Chief Financial and Administrative Officer TransitionSavara Inc. announced that Chief Financial and Administrative Officer Dave Lowrance is stepping down effective July 15, 2026, for health-related reasons. His responsibilities will be split, with Chief Operating Officer Robert Lutz assuming the CFO role while administrative duties are distributed among senior leadership. Lutz brings over two decades of pharmaceutical industry experience and previously served as CFO at iBio and Strongbridge Biopharma.Benzinga · Jun 8, 2026

Savara Announces Participation in the 2026 Jefferies Global Healthcare ConferenceSavara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3rd. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).Benzinga · May 27, 2026

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceSavara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in a fireside chat at the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference on May 19th at 10:00am ET in New York. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).Benzinga · May 11, 2026

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the UK's MHRA by end of Q1 2026. MOLBREEVI, a recombinant GM-CSF treatment for autoimmune PAP, has received Fast Track and Breakthrough Therapy designations from the FDA.Benzinga · Mar 6, 2026

Savara Announces Participation in 2026 Citizens Life Sciences ConferenceSavara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).Benzinga · Mar 4, 2026

Savara Announces Participation in Upcoming Investor Healthcare ConferencesSavara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and fireside chats at two upcoming investor healthcare conferences. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).Benzinga · Feb 4, 2026

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmLaw firm Bragar Eagel & Squire is investigating Savara, Inc. for potential breach of fiduciary duties by its board of directors. The investigation concerns allegations that Savara failed to disclose that its MOLBREEVI BLA lacked sufficient information regarding chemistry, manufacturing, and controls, making FDA approval unlikely. On May 27, 2025, the FDA issued a refusal to file letter, causing Savara's stock to plummet 31.69% to $1.94 per share. The class action covers the period from March 7, 2024 to May 23, 2025.GlobeNewswire Inc. · Jan 24, 2026

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare ConferenceSavara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will present at the 44th Annual J.P. Morgan Healthcare Conference. The company's lead program, MOLBREEVI, is a Phase 3 development treatment for autoimmune pulmonary alveolar proteinosis.Benzinga · Dec 17, 2025

Savara Announces Participation in Upcoming Investor Healthcare ConferencesSavara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.Benzinga · Nov 20, 2025

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmThe Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for allegedly making false and misleading statements about their BLA (Biologics License Application) for MOLBREEVI, which was deemed insufficient by the FDA and likely to require additional capital.Benzinga · Nov 7, 2025

to start trading

SV

SVRASavara Inc.

SVRA

Pay with—

Available Balance0.00

Your PositionYou don't own any SVRA yet.

Related Tickers

Earnings